University of Colorado

Musc Foundation for Research Development

Q32 Bio Inc.

National Jewish Health

National Jewish Medical and Research Center

Vernon Michael Holers

Justin Andrew Caravella

Frederick Robbins Taylor

Susan L Kalled

Shelia Marie Violette

Joshua M Thurman

Michael Storek

Michael Steven Curtis

Ellen Garber Stark

Kelly C Fahnoe

Cheng Ran Huang

Erwin W Gelfand

Gary Gilkeson

Xiaojiang Chen

Christian Taube

Stephen Tomlinson

Philip F Stahel

Gary Steven Gilkeson

Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator

Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide

Fusion protein constructs comprising anti-C3d antibody and factor H

Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.

Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

Inhibition of factor B, the alternative complement pathway and methods related thereto

Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.

Three-dimensional structure of complement receptor type 2 and uses thereof

Anti-factor B antibodies

Growing community of inventors

Denver, CO, United States of America

Vernon Michael Holers